← Eichor
Study identifier: NCT07611838 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction

Condition: Allergic Bronchopulmonary Aspergillosis (ABPA) · Machine Learning · Multi-omics  ·  Sponsor: Qianfoshan Hospital

PhaseN/A
Planned participants300
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

To develop and externally validate a machine learning model for predicting the 1-year risk of relapse in patients with stable ABPA, and to further evaluate its value in risk stratification and clinical decision-making.

This description comes directly from the study's public registry record.

Talk to the study team

Qian Qi  ·  +86 13706380314  ·  qiqianqlh@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China, Jinan, Shandong 250014Jinan, Shandong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07611838